Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC
In patients receiving extended-duration ICI beyond 2 years, late IRAEs were common and often occurred in patients without previous history of IRAE. These findings support consideration of ICI discontinuation at 2 years.
Authors
- Lova Sun (ORCID: https://orcid.org/0000-0002-5015-2964)
- Jonathan Sussman (ORCID: https://orcid.org/0000-0002-7702-8816)
- Kyle Robinson
- Christine Ciunci
- Melina E. Marmarelis (ORCID: https://orcid.org/0000-0003-2187-3583)
- Adam Barsouk (ORCID: https://orcid.org/0000-0003-2333-7530)
- John A. Kosteva
- Benjamin Aaron Bleiberg (ORCID: https://orcid.org/0000-0002-9565-9304)
- Christopher D’Avella (ORCID: https://orcid.org/0000-0003-2276-0257)
- Charu Aggarwal (ORCID: https://orcid.org/0000-0002-3181-9460)
- Omar Elghawy (ORCID: https://orcid.org/0000-0002-0786-8035)
- Lauren Reed-Guy
- Corey J. Langer (ORCID: https://orcid.org/0000-0002-8483-6811)
- Aditi Singh (ORCID: https://orcid.org/0000-0001-7438-2863)
- Roger B. Cohen
Institutions
- University of Pennsylvania (US)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-05-26
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100851
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.09